Five Biotech Stocks Surge 105% to 235% to New Highs

RTTNews··Read original
2▲5 ▼0Impact / 5
Summary · why it matters

Five biotech stocks profiled by RTTNews reached new 52-week highs last week, with gains ranging from 105% to 235% since their respective publication dates. Twist Bioscience soared 235% to a high of $104.23, driven by strong revenue and an upcoming quarterly report. Biodesix climbed 124% to $23.34 following better-than-expected results, raised guidance, and positive clinical validation data. Mirum Pharmaceuticals rose 133% to $124.44 on consistent revenue growth, the Bluejay Therapeutics acquisition, and positive trial results for Brelovitug and Volixibat. Candel Therapeutics advanced 108% to $9.99 after extended survival data for Aglatimagene and a commercialization agreement with EVERSANA. Indivior Pharmaceuticals gained 105% to $42.81, supported by solid earnings, upbeat guidance, and real-world evidence favoring Sublocade.

Impact on assets 5

Biotech & Genomic Medicine▲ · 4 stocks
Biodesix Inc
BDSX
▲ PositiveCapitalrelevance

Better-than-expected results, raised guidance, and positive clinical validation data drove stock to new high.

Candel Therapeutics Inc
CADL
▲ PositiveTechnologyrelevance

Extended survival data for Aglatimagene and a commercialization agreement with EVERSANA drove stock higher.

Mirum Pharmaceuticals Inc
MIRM
▲ PositiveCapitalrelevance

Consistent revenue growth, Bluejay Therapeutics acquisition, and positive trial results for Brelovitug and Volixibat drove stock.

Synthetic Biology (non-pharma)▲ · 1 stocks
© 2026 MarketIVNews